Concomitant potent and moderate CYP3A inducers (without a potent CYP3A inhibitor): 600mg twice daily. Children: <2yrs or <2kg: not recommended.

See Contraindications. Potentiated by CYP2C9 (eg, fluconazole, amiodarone) or strong or moderate CYP3A inhibitors (eg, ketoconazole, itraconazole, amprenavir, erythromycin, diltiazem); concomitant ...

CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA ...

Sunlenca is also a moderate CYP3A enzyme inhibitor and may raise the chance of side effects from certain medicines broken down by CYP3A enzymes in your body if these medicines are started within ...

Dosage modifications are recommended for patients with hepatic impairment and those on concomitant moderate CYP3A inhibitors. The use of Journavx for moderate to severe pain has not been studied ...